Absci Q2 Earnings Call Highlights

Impact · against what's priced in

Absci receives significant fundamental validation through a $40 million strategic investment from Eli Lilly and positive interim Phase 1 data for ABS-201. The long half-life and expansion into endometriosis significantly increase the asset's commercial potential and the company's cash runway.

ABSI+0.80

No priced-in read yet

In context

The strategic investment from Eli Lilly and a 65-day half-life for ABS-201 provide strong validation and a competitive advantage for patient compliance. Additionally, the expansion into the endometriosis market and a cash balance of $201.1 million reduce risk and increase the total addressable market.

Read from the article alone

• biotech
• ABSI
• LLY
• antibody
• clinical trials
• drug discovery
• endometriosis
• equity offering
• hair loss
• phase 1
• phase 2